Using a blood test to guide treatment decisions for DLBCL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial is for people with newly diagnosed DLBCL who have a specific blood marker before treatment and achieve complete remission after standard chemotherapy. The study uses a blood test to help guide whether additional treatment is needed after chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been recently diagnosed with diffuse large B-cell lymphoma (DLBCL) and have a blood test that shows a specific cancer marker (called circulating tumor DNA) before starting treatment.
- After completing the usual 6 cycles of R-CHOP chemotherapy, your scans must show that the lymphoma has disappeared completely (a complete metabolic remission).
- You cannot have had a stem cell transplant before joining this study.
- You cannot have had other cancers (except for a common skin cancer called basal cell carcinoma or cervical cancer in situ).
- You must be generally healthy, without serious heart, bleeding, or immune problems, and not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a blood test (ctDNA) and PET scans to predict how well standard first-line treatment works for diffuse large B-cell lymphoma (DLBCL). It aims to find out if these tests can guide better care.
This study tests a new treatment combination (CD-RCHOP, likely a form of chemotherapy with an antibody) for people with a high-risk type of diffuse large B-cell lymphoma that has certain genetic changes (TP53 mutation and 17p deletion). It aims to see if this approach is safe and effective for this specific group.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This study tests whether using a special blood test (ctDNA) to guide targeted therapy can improve outcomes for people with a type of lymphoma called DLBCL. If you qualify, you may receive a standard chemo-immunotherapy regimen (R-CHOP) possibly combined with other drugs, and your treatment plan may be adjusted based on your ctDNA levels.
This study looks at the biology of certain lymphomas to better understand why some people respond well to treatment and others don't. It involves giving a small additional blood or tissue sample to help researchers find genetic clues that could improve future care.
This study looks for biomarkers (biological signs) in blood or tissue samples from people with diffuse large B-cell lymphoma (DLBCL) to help predict how the disease behaves and how well treatment might work. Participation involves giving extra biopsy or blood samples during routine care.
Hear when a new Lymphoma, Large B-Cell, Diffuse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.